GlassScriptPhysician profile
Karen L Schneider
NPI 1245329358
$1,378.15
in general payments reported to CMS, 2019-2025
12 companies · $610 in 2025
The $610 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $35.05 · 2023: $202 · 2024: $532 · 2025: $610.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,325 · Education: $18.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.84 |
| Education | $18.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $436.63 | 2023-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $287.81 | 2023-2025 | Xifaxan, Plenvu, Trulance |
| Janssen Biotech, INC. | $195.60 | 2024-2025 | Stelara, Tremfya |
| Regeneron Healthcare Solutions, INC. | $92.52 | 2022-2025 | Dupixent |
| Lilly USA, LLC | $70.87 | 2025 | Omvoh, Zepbound |
| Ardelyx, INC. | $59.86 | 2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $53.71 | 2023-2024 | Linzess |
| Celltrion USA INC. | $51.85 | 2024-2025 | Vegzelma, Zymfentra |
| Intercept Pharmaceuticals, INC. | $45.79 | 2025 | |
| Qol Medical, LLC | $34.10 | 2025 | Sucraid |
| Madrigal Pharmaceuticals | $32.01 | 2024 | Resmetirom |
| Braintree Laboratories, INC. | $17.40 | 2024 | Sutab, Suflave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karen Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.